JP2017531693A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531693A5
JP2017531693A5 JP2017538177A JP2017538177A JP2017531693A5 JP 2017531693 A5 JP2017531693 A5 JP 2017531693A5 JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017531693 A5 JP2017531693 A5 JP 2017531693A5
Authority
JP
Japan
Prior art keywords
seq
antigen
population
epicensus
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017538177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531693A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/054067 external-priority patent/WO2016054654A1/en
Publication of JP2017531693A publication Critical patent/JP2017531693A/ja
Publication of JP2017531693A5 publication Critical patent/JP2017531693A5/ja
Pending legal-status Critical Current

Links

JP2017538177A 2014-10-03 2015-10-05 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン Pending JP2017531693A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462059497P 2014-10-03 2014-10-03
US201462059506P 2014-10-03 2014-10-03
US62/059,506 2014-10-03
US62/059,497 2014-10-03
PCT/US2015/054067 WO2016054654A1 (en) 2014-10-03 2015-10-05 Hiv vaccines comprising one or more population episensus antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020170852A Division JP7212020B2 (ja) 2014-10-03 2020-10-09 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン

Publications (2)

Publication Number Publication Date
JP2017531693A JP2017531693A (ja) 2017-10-26
JP2017531693A5 true JP2017531693A5 (https=) 2018-11-15

Family

ID=55631703

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017538177A Pending JP2017531693A (ja) 2014-10-03 2015-10-05 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
JP2020170852A Active JP7212020B2 (ja) 2014-10-03 2020-10-09 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
JP2023003194A Active JP7441340B2 (ja) 2014-10-03 2023-01-12 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020170852A Active JP7212020B2 (ja) 2014-10-03 2020-10-09 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
JP2023003194A Active JP7441340B2 (ja) 2014-10-03 2023-01-12 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン

Country Status (16)

Country Link
US (3) US10894078B2 (https=)
EP (1) EP3200878B1 (https=)
JP (3) JP2017531693A (https=)
KR (1) KR102633096B1 (https=)
CN (1) CN108064181A (https=)
AU (2) AU2015327797A1 (https=)
CA (1) CA2963573C (https=)
EA (1) EA201790680A1 (https=)
HK (1) HK1254806A1 (https=)
IL (1) IL251469B2 (https=)
MA (1) MA40783A (https=)
MX (3) MX391149B (https=)
SG (1) SG11201702729YA (https=)
UA (1) UA126890C2 (https=)
WO (1) WO2016054654A1 (https=)
ZA (1) ZA202206809B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
WO2020243485A1 (en) * 2019-05-29 2020-12-03 Massachusetts Institute Of Technology Hiv-1 specific immunogen compositions and methods of use
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
MX2022002270A (es) 2019-08-29 2022-03-22 Vir Biotechnology Inc Vacunas contra el virus de la hepatitis b.
US12053517B2 (en) * 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using
JP2024534189A (ja) 2021-08-31 2024-09-18 ヴィア・バイオテクノロジー・インコーポレイテッド 組換えｈｃｍｖベクター及びその使用
TW202436326A (zh) * 2023-02-13 2024-09-16 長怡 王 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者
CN116524994B (zh) * 2023-02-20 2026-01-30 中国科学院天津工业生物技术研究所 一种基于贪婪算法的菌株构建排程设计方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
AU2011203095A1 (en) 2003-09-17 2011-07-21 Duke University Consensus/Ancestral Immunogens
BRPI0414443A (pt) * 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
EA012066B1 (ru) 2003-10-10 2009-08-28 Паудерджект Вэксинс, Инк. Способ, вызывающий т-клеточный ответ
EP2497831B1 (en) 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors
CN101969996A (zh) * 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
CA3057039C (en) 2006-07-28 2023-02-28 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
WO2008121282A2 (en) * 2007-03-30 2008-10-09 Merck & Co., Inc. Broadly representative antigen sequences and method for selection
NZ602504A (en) 2008-11-18 2014-01-31 Beth Israel Hospital Antiviral vaccines with improved cellular immunogenicity
AU2010305030A1 (en) * 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
TR201802741T4 (tr) * 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
US8557787B2 (en) 2011-05-13 2013-10-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2820035B1 (en) 2012-03-02 2019-01-09 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions
SG10201705880QA (en) * 2013-01-07 2017-08-30 Beth Israel Deaconess Medical Ct Inc Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
DK2964769T3 (en) 2013-03-05 2018-12-10 Univ Oregon Health & Science Cytomegalovirus vectors enabling control of T cell targeting
CA2941116A1 (en) 2014-02-28 2015-09-03 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
CN113528466B (zh) 2014-07-16 2024-12-24 俄勒冈健康与科学大学 包含外源抗原的人巨细胞病毒
CN106999571B (zh) 2014-09-26 2020-10-02 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
DK3584252T3 (da) 2015-12-15 2021-11-15 Janssen Vaccines & Prevention Bv Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf

Similar Documents

Publication Publication Date Title
JP2017531693A5 (https=)
CA2949851C (en) Htert sequences and methods for using the same
Doria-Rose et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge
Hanke Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines
McShane et al. Prime-boost immunisation strategies for tuberculosis
Earl et al. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate
Ross et al. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference
Paris et al. Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1
Karpenko et al. Novel approaches in polyepitope T-cell vaccine development against HIV-1
Knudsen et al. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen
Latanova et al. Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity
Larijani et al. HIV-1 p24-nef DNA vaccine plus protein boost expands T-cell responses in BALB/c
Ajbani et al. Immunogenicity of virus-like Semliki Forest virus replicon particles expressing Indian HIV-1C gag, env and polRT genes
Sundbäck et al. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles
Liu et al. The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice
Shephard et al. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice
Mahdavi et al. HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model
Anderson et al. Overcoming original (antigenic) sin
van Harmelen et al. Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa
Blomquist et al. Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide
Dereuddre-Bosquet et al. HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations
Clutton et al. Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines
Klein Prospects and challenges for prophylactic and therapeutic HIV vaccines
Mayr et al. Antibodies targeting the envelope of HIV‐1
Stenler et al. Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses